Latest Deals

Credit: Shutterstock/nobeastsofierce

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results. Both firms will be involved in the discovery, potential development and commercialisation of the RNAa therapeutic candidates. 

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. Gene therapy clients will gain access to coordinated scientific expertise, drug development services and AAV manufacturing capabilities, advancing the development of new gene therapies. 

Assertio Holdings has reached a definitive agreement to purchase all outstanding shares of Spectrum Pharmaceuticals in an all-stock and contingent value rights (CVR) deal. Spectrum is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel and targeted oncology treatments. 

Hasten Biopharmaceutic has purchased the commercial rights for Rocephin in mainland China from Swiss healthcare firm Roche. There will now be a transition period between the two firms, following the completion of the deal earlier in 2023.  Rocephin is a long-acting, broad spectrum cephalosporin antibiotic for parenteral use.